臺灣博碩士論文加值系統

代謝症候群是一群代謝性疾病的組合出現在同一個人身上，其主要代謝異常現象，包含肥胖、血脂異常、高血糖、高血壓、胰島素阻抗或葡萄糖耐受不良等危險因子，一個人同時只要具有三項以上的危險因子，就可被推定為代謝症候群。之前有研究發現，綠藻(Chlorella)與洛神花(Roselle)，具有抑制脂肪細胞三酸甘油酯堆積之效應，進而抑制脂肪細胞之形成，而高油脂飲食所誘發之肥胖動物模式也已被成功建立。而且在收縮壓、禁食血漿葡萄糖、葡萄糖耐受性以及胰島素阻抗皆有改善之現象，顯示使用之洛神花、綠藻組成之複方能改善胰島素阻抗及代謝症候群之現象。在這個研究中，我們假設使用之洛神花、綠藻組成之複方透過減少脂肪細胞的形成，可影響代謝症候群的產生。本研究共有48位具有代謝症候群之個案，每天受試者攝取4公克，分三餐食用。蒐集臨床上代謝症候群的指標，如腰圍，BMI，空腹血糖，體脂肪，血壓，血脂，胰島素抗性等。實驗結果發現到綠藻或綠藻加洛神花試劑可以减少腰圍、增加高密度脂蛋白膽固醇、降低血壓。透過常見食品預防代謝症候群的發生，減緩慢性疾病，來佐證先前假說。期望可應用於預防醫療(preventive medicine)。

Metabolic syndrome is a combination of metabolic diseases in the same person, its main metabolic abnormalities, including obesity, dyslipidemia, hyperglycemia, hypertension, insulin resistance or glucose intolerance, and so on. The above risk factors can be presumed to be metabolic syndrome. Previous studies have found that Chlorella and Roselle have the effect of inhibiting the accumulation of fatty acid triglycerides, thereby inhibiting the formation of fat cells, and the high fat diet-induced obese animal model has been successfully established. Moreover, systolic blood pressure, fasting plasma glucose, glucose tolerance, and insulin resistance have all been improved, indicating that the combination of the use of Roselle and Chlorella can improve insulin resistance and metabolic syndrome. In this study, we hypothesized that the combination of Roselle and Chlorella can affect the production of metabolic syndrome by reducing the formation of fat cells. There were 48 cases of metabolic syndrome in this study. The subjects took 4 g/day and were eaten in three meals. Collect clinical indicators of metabolic syndrome, such as waist circumference, BMI, fasting blood glucose, body fat, blood pressure, blood lipids, insulin resistance, etc. The results of the experiment showed that Chlorella or Chlorella+ Roselle can reduce waist circumference, increase high-density lipoprotein cholesterol, and lower blood pressure. To support the previous hypothesis by preventing the occurrence of metabolic syndrome in common foods and slowing down chronic diseases. It is expected to be applicable to preventive medicine.

誌謝……………………………………………… i
中文摘要…………………………………………………………………… ii
英文摘要……………………………………………………………………… iii
目錄………………………………………………………………………… iv
圖目錄…………………………………………………………………… iv
圖一 洛神花 …………………………………………………………………… 15
圖二 綠藻…………………………………………………………………… 19
圖三 試驗試劑的外觀…………………………………………………………………… 24
圖四 說明綠藻、綠藻加洛神花與安慰劑組對體位測量之變化 64
圖五 說明綠藻、綠藻加洛神花與安慰劑組對體位測量在時間上的趨勢變化65
圖六 說明綠藻、綠藻加洛神花與安慰劑組對血脂肪之變化 66
圖七 說明綠藻、綠藻加洛神花與安慰劑組對血脂肪在時間上的趨勢變化 67
圖八 說明綠藻、綠藻加洛神花與安慰劑組對血糖之變化 68
圖九 說明綠藻、綠藻加洛神花與安慰劑組對血糖在時間上的趨勢變化 69
圖十 說明綠藻、綠藻加洛神花與安慰劑組對血壓之變化 70
圖十一 說明綠藻、綠藻加洛神花與安慰劑組對血壓在時間上的趨勢變化 71
圖十二 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對體位測量之變化 72
圖十三 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對體位測量在時間上的趨勢變化 73
圖十四 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血脂肪之變化 74
圖十五 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血脂肪在時間上的趨勢變化 75
圖十六 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血糖之變化 76
圖十七 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血糖在不同時間的趨勢變化 77
圖十八 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血壓之變化 78
圖十九 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血壓在時間上趨勢變化 79
圖二十 說明綠藻、綠藻加洛神花與安慰劑組對熱量之變化 80
表目錄…………………………………………………………………… v
表一 與肥胖相關的疾病 2
表二 肥胖的定義 4
表三 代謝症候群臨床診斷標準 7
表四 衛生署國民健康局2006 年版修正前、後之代謝症候群判定標準對照表 9
表五 實驗前三組人數與性別與代謝症候群相關指標的比較 52
表六 說明綠藻、綠藻加洛神花與安慰劑組對體位測量之比較 53
表七 說明綠藻、綠藻加洛神花與安慰劑組對血脂肪相關指標之比較 54
表八 說明綠藻、綠藻加洛神花與安慰劑組對血糖相關指標之比較 55
表九 說明綠藻、綠藻加洛神花與安慰劑組對血糖相關指標之比較 56
表十 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對體位測量之比較 57
表十一 說明女性族群在綠藻組、綠藻加洛神花與安慰劑組對血脂肪相關指標之比較 58
表十二 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血糖相關指標之比較 59
表十三 說明女性族群在綠藻、綠藻加洛神花與安慰劑組對血壓相關指標 60
表十四 說明族群綠藻、綠藻加洛神花與安慰劑組對熱量之比較 61
表十五 說明體重在校正熱量後，熱量P<0.05表示有影響個別參數的數值 62
表十六 說明腰圍在校正熱量後，熱量P<0.05表示有影響個別參數的數值 62
表十七 說明綠藻、綠藻加洛神花與安慰劑組對於代謝症候群相關指標的影響性 63
第一章 前言 1
第二章 文獻回顧 2
一、肥胖
1 肥胖的成因 3
2 肥胖的定義 4
3 不同肥胖指標對健康預後之分析 5
二、代謝症候群
1 代謝症候群之發展 6
2 代謝症候群之定義 7
3 代謝症候群之病因及致病機轉 10
3.1代謝症候群與腰圍 11
3.2代謝症候群與血糖 12
3.3代謝症候群與三酸甘油脂及高密度脂蛋白 13
3.4代謝症候群與血壓 14
三、食材介紹
1 洛神花 15
2 綠藻 18
四、研究目的 21
第三章 材料與方法
一、研究族群 21
二、收集時間 22
三、研究方法 22
四、試劑來源 23
五、身體評估內容
1 體重與體脂測定 24
2 腰臀圍測定 24
3 血脂肪測定 25
4 血壓測定 26
5 血糖測定 26
六、飲食分析 26
七、統計分析 27
第四章 結果
一、受試者試驗前的基本相關資料之分析 28
二、代謝症候群相關指標分析結果
1. 綠藻與洛神花對肥胖相關指標之影響 28
2. 綠藻與洛神花對血脂相關指標之影響 29
3. 綠藻與洛神花對血糖相關指標之影響 30
4. 綠藻與洛神花對血壓相關指標之影響 31
三、綠藻與洛神花對女性族群之影響 32
四、綠藻與洛神花在校正熱量後的影響性 34
第五章 討論 35
第六章 結論 40
參考文獻 42
附錄 52

1. Mottillo S, Filion K. B, Genest J. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. Journal of the American College of Cardiology 56:1113-1132,2010.
2. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome. Circulation 112:2735-2752,2005.
3. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes. Diabetes Care 31:1898-1904,2008.
4. National Institutes of Health. What are the health risks of overweight and obesity? From http://www.nhlbi.nih.gov /health /health-topics /topics/obe/risks,2012.
5. Blackburn GL. (1999) Benefits of weight loss in the treatment of obesity. The American Journal of Clinical Nutrition 69:347–349,1999.
6. Goldstein DJ. Beneficial health effects of modest weight loss. International journal of obesity and related metabolic disorders 16: 397–415,1992.
7. World Health Organisation. WHO Factsheet No. 311,2011.
8. Rodgers A, Vaughan P, Prentice T, Edejer T, Evans D, Lowe J. World health report 2002: reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization.
9. Locke AE, Kahali B, Berndt SI. Genetic studies of body mass index yield new insights for obesity biology. Nature 518:197–206,2015.
10. Spence C, Okajima K, Cheok AD. Eating with our eyes: from visual hunger to digital satiation. Brain and Cognition 110:53–63,2016.
11. Verhagen JV. The neurocognitive bases of human multimodal food perception: consciousness. Brain Research Reviews 53:271–286,2007.
12. Campbell MK. Biological, environmental, and social influences on childhood obesity. Pediatric Research 79:205–11,2016.
13. Davison KK, Birch LL. Childhood overweight: a contextual model and recommendations for future research. Obesity Reviews 2:159–171,2001.
14. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA. Dynamics of fat cell turnover in humans. Nature 453:783–787,2008.
15. Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M. Hypertrophy and hyperplasia of abdominal adipose tissues in women. International Journal of Obesity 32:283–291,2008.
16. Thomas G. N. Impact of sex-specific body composition on cardiovascular risk factors: the Hong Kong Cardiovascular Risk Factor Study. Metabolism 55, 563–569,2006.
17. Grundy SM, Hansen B, Smith SC, Jr.,Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551-556,2004.
18. Reis JP, Macera CA, Araneta MR. Comparison of overall obesity and body fat distribution in predicting risk of mortality. Obesity 17: 1232–1239,2009.
19. Reis JP, Araneta MR, Wingard DL. Overall obesity and abdominal adiposity as predictors of mortality in U.S. White and Black Adults. Annals of Epidemiology 19: 134–42,2009.
20. Pischon T, Boeing H, Hoffmann K. General and abdominal adiposity and risk of death in Europe. The New England Journal of Medicine 359:2105–2120,2008.
21. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. The American Journal of Clinical Nutrition 79:379–384,2004.
22. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews 21: 697–738,2000.
23. Hanson RL, Imperatore G, Bennett PH. Components of the ‘Metabolic Syndrome’ and incidence of type 2 diabetes. Diabetes 51:3120–3127,2002.
24. Laaksonen DE. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. American journal of epidemiology 156:1070–1077,2002.
25. Lakka H-M. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. The Journal of the American Medical Association 288:2709–2716,2002.
26. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. The American Journal of the Medical 119:812–819,2006.
27. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome. Circulation 112: 2735-2752,2005.
28. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice 2014:943162,2014.
29. Alberti KG, Eckel RH, Grundy SM. Harmo n i z ing t h e metabolicsyndrome. Circulation 120: 1640-1645,2009.
30. Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Jr, Lenfant C, American Heart A, National Heart L, Blood I. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438,2004.
31. Grundy SM. Metabolic syndrome pandemic. Arteriosclerosis, Thrombosis, and Vascular Biology 28:629–636,2008.
32. Després JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9:452–459,1993.
33. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. The American journal of clinical nutrition 83:461S–495S,2006.
34. Indumathy J, Pal GK,Pal P, Ananthanarayanan PH, Parija SC, Balachander J, Dutta TK. Contribution of insulin resistance to decreased baroreceptor sensitivity & cardiometabolic risks in pre-obesity & obesity. The Indian Journal of Medical Research 148:151-158,2018.
35. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Medicine 9: 48-61,2011.
36. Ge Q, Brichard S, Yi X, Li Q. microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. Journal of Immunology Research doi: 10.1155/2014/987285,2014.
37. Shulman GI. Ectopic fat in insulin resistance,dyslipidemia, and cardiometabolic disease. The New England Journal of Medicine 371:1131-1141,2014.
38. Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Archives of Physiology and Biochemistry 114:183-194,2008.
39. Kusminski CM, Mcternan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clinical Science 109: 243-256,2005.
40. Olivares-Reyes JA, Arellano-Plancarte A,Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Molecular and Cellular Endocrinology 302: 128-139,2009.
41. Aouadi M, Tencerova M, Vangala P, Yawe JC, Nicoloro SM, Amano SU. Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice. Proceedings of the National Academy of Sciences 110:8278–8283,2013.
42. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365:1415-1428,2005.
43. Buchanan TA, Watanabe RM, Xiang AH. Limitation in surrogate measures of insulin resistance. The Journal of Clinical Endocrinology and Metabolism 95:4874-4876,2010.
44. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 409:307-312,2001
45. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10,1997.
46. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia :mutation analysis of a membrane protein. The Annual Review of Genetics 24:133-170,1990.
47. King, G.L., Loeken, M.R. Hyperglycemia induced oxidative stress in diabetic complications. Histochemistry and Cell Biology 122: 333-338,2004.
48. Mahadevan, N., Shivali, K. P., & Kamboj, P. Hibiscus sabdariffa Linn.-an overview. Natural product radiance 8:77-83,2009.
49. 陳曉菁(2008)．洛神葵保健機能性之應用‧臺東區農業專訊，(65)，13-15。
50. 王朝鐘(2008)．洛神花之醫學功能與產品開發‧農業生技產業季刊，(14)，62-69。
51. McKay, D. L., Chen, C. O., Saltzman, E., & Blumberg, J. B. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. The Journal of Nutrition 140:298-303,2010.
52. Hsu, R. J., Hsu, Y. C., Chen, S. P., Fu, C. L., Yu,J. C., Chang, F. W. The triterpenoids of Hibiscus syriacus induce apoptosis and inhibit cell migration in breast cancer cells. The official journal of the International Society for Complementary Medicine Research 15:65,2015.
53. Lin HH, Huang HP, Huang CC, Chen JH, Wang CJ.(2005) Hibiscus polyphenol-rich extract induces apoptosis in human gastric carcinoma cells via p53 phosphorylation and p38 MAPK/FasL cascade pathway. Molecular Carcinogenesis 43: 86-99,2005.
54. Lin TL, Lin HH, Chen CC, Lin MC, Chou MC, Wang CJ. Hibiscus sabdariffa extract reduces serum cholesterol in men and women. Nutrition Research 27:140-145,2007.
55. Onyenekwe PC, Ajani EO, Ameh DA, Gamaniel KS. Antihypertensive effect of roselle (Hibiscus sabdariffa) calyx infusion in spontaneously hypertensive rats and a comparison of its toxicity with that in Wistar rats. Cell Biochemistry and Function 17:199-206,1999.
56. Jonadet, M., Bastide, J., Bastide, P., Boyer, B.,Carnat, A. P., Lamaison, J. L. In vitro enzyme inhibitory and in vivo cardioprotective activities of hibiscus (Hibiscus sabdariffa L. ). Journal de Pharmacie de Belgique 4: 120-124,1989.
57. Ojeda, D., Jiménez-Ferrer, E., Zamilpa, A., Herrera-Arellano, A., Tortoriello, J., Alvarez, L. Inhibition of angiotensin convertin enzyme (ACE) activity by the anthocyanins delphinidin-and cyanidin-3-O-sambubiosides from Hibiscus sabdariffa. Journal of Ethnopharmacology 127:7-10,2010.
58. Ali, B. H., Mousa, H. M., & El Mougy, S. The effect of a water extract and anthocyanins of hibiscus sabdariffa L. on paracetamol induced hepatoxicity in rats. Phytotherapy Research 17:56-59,2003.
59. Adeyemi, D. O., Ukwenya, V. O., Obuotor, E. M.,& Adewole, S. O. Anti-hepatotoxic activities of Hibiscus sabdariffa L. in animal model of streptozotocin diabetes-induced liver damage. BMC complementary and Alternative Medicine 14: 277,2014.
60. Sundari, K., Govindaraju G., Bharathi B. Hepatoprotective effect of ethanolic extracts of Sphaeranthus indicus (Linn) on paracetamol-induced liver toxicity in rats. International Journal of Applied Science and Technology 2: 315-321,2011.
61. Liu, C. L., Wang, J. M., Chu, C. Y., Cheng, M. T., &Tseng, T. H. In vivo protective effect of protocatechuic acid on tert-butyl hydroperoxideinduced rat hepatotoxicity. Food and Chemical Toxicology 40: 635-641,2002.
62. Chen CC, Chou FP, Ho YC, Lin WL, Wang CP, Hao ES, Huang AC, Wang CJ. Inhibitory effects of Hibiscus Sabdarriffa L.extract on low-density lipoprotein oxidation and anti-hyperlipidemia in fructose-fed and cholesterol-fed rats. Journal of the Science of Food and Agriculture 84:1989-1996,2004.
63. Wang CJ , Wang JM, Lin WL, Chu CY, Chou FP, Tseng TH. Protective effect of Hibiscus anthocyanins against tertbutylhydroperoxide-induced hepatic toxicity in rats. Food and Chemical Toxicology 38:411-416,2000.
64. Lee MJ, Chou FP, Tseng TH, Hsieh MH, Lin MC, Wang CJ. Hibiscus protocatechuic acid or esculetin can inhibit oxidative LDL induced by either copper ion or nitric oxide donor. Journal of Agricultural and Food Chemistry 50:2130-2136,2002.
65. Lo CW, Huang HP, Lin HM, Chien CT, Wang CJ. Effect of Hibiscus anthocyanins-rich extracts induced apoptosis of proliferation smooth muscle cell via activation of p38 MAPK and p53 pathway. Molecular Nutrition & Food Research 51:1452-1460,2007.
66. Chen CC, Hsu JD, Wang SF, Chiang HC, Yang MY, Kao ES, Ho YC, Wang CJ. Hibiscus sabdariffa extract inhibits the development 100 of atherosclerosis in cholesterol-fed rabbits. Journal of Agricultural and Food Chemistry 51:5472-5477,2003.
67. Chen CC, Chou FP, Ho YC, Lin WL, Wang CP, Kao ES, Huang AC, Wang CJ. Inhibitory effect of Hibiscus sabdariffa L. extract on LDL oxidation and anti-hyperlipidemia in fructose-fed and cholesterol fed rats. Journal of the Science of Food and Agriculture 84:1989-1996,2004.
68. Lin TL, Lin HH, Chen CC, Lin MC, Chou MC, Wang CJ. Hibiscus sabdariffa extract reduces serum cholesterol in men and women. Nutrition Research 27:140-145,2007.
69. 林貴萍。2002。綠藻之機能性與其分析方法。食品工業。34:21-25。新竹。
70. Morimura, Y., Tamiya, N. Preliminary experiments on the use of Chlorella as human food. Food Technology 8: 179–182,1954.
71. Becker EW. Micro-algae for human and animal consumption. Micro-algal Biotechnology. Cambridge University Press, Cambridge: 222–256,1988.
72. Kwak JH,Baek SH,Woo Y,Han JK,Kim BG,Kim OY,Lee JH. Beneficial immunostimulatory effect of short-term Chlorella supplementation: enhancement of Natural Killer cell activity and early inflammatory response (Randomized, double-blinded, placebo-controlled trial). Nutrition Journal 11: 53,2012.
73. Otsuki T, Shimizu K, Iemitsu M, Kono I. Salivary Secretory Immunoglobulin a secretion increases after 4-weeks ingestion of chlorella-derived multicomponent supplement in humans: a randomized cross over study. Nutrition Journal 10: 91,2011.
74. Kim S, Kim J, Lim Y, Kim YJ, Kim JY, Kwon O. A dietary cholesterol challenge study to assess Chlorella supplementation in maintaining healthy lipid levels in adults: a double-blinded, randomized, placebo-controlled study. Nutrition Journal J.15:54,2016.
75. Ryu NH, Lim Y, Park JE, Kim J, Kim JY, Kwon SW, Kwon O. Impact of daily Chlorella consumption on serum lipid and carotenoid profiles in mildly hypercholesterolemic adults: a double-blinded, randomized, placebo-controlled study. Nutrition Journal 13:57–64,2014.
76. Chiu YJ, Chung HH, Yeh CH, Cheng JT, Lo SH. Improvement of insulin resistance by Chlorella in fructose-rich chow-fed rats. Phytotherapy Research 25:1306-1312,2011.
77. Vecina JF, Oliveira AG, Araujo TG, Baggio SR, Torello CO, Saad MJ, Queiroz ML. Chlorella modulates insulin signaling pathway and prevents high-fat diet-induced insulin resistance in mice. Life Science 95:45-52,2014.
78. Noguchi N, Konishi F, Kumamoto S, Maruyama I, Ando Y, Yanagita T. Beneficial effects of Chlorella on glucose and lipid metabolism in obese rodents on a high-fat diet. Obesity Research & Clinical Practice. 7:e95-e105
79. Merchant RE, Andre CA, Sica DA. (2002) Nutritional supplementation with Chlorella pyrenoidosa for mild to moderate hypertension. Journal of Medicinal Food 5:141-152,2013.
80. Shimada M, Hasegawa T, Nishimura C, Kan H, Kanno T, Nakamura T, Matsubayashi T. Anti-hypertensive effect of gamma-aminobutyric acid (GABA)-rich Chlorella on high-normal blood pressure and borderline hypertension in placebo-controlled double blind study. Clinical and Experimental Hypertension 31:342-354,2009.
81. Epel ES, McEwen B, Seeman T, Matthews K, Castellazzo G, Brownell KD, Bell J, Ickovics JR. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosomatic Medicine 62:623-32,2000.
82. T.M. Abraham, A. Pedley, J.M. Massaro. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation 132: 1639-1647,2015.
83. Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiological Reviews 84:277–359,2004.
84. Wu J, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150:366–376,2012.
85. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Molecular and cellular endocrinology 402:113-119,2015.
86. Blaak E. Gender differences in fat metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 4:499-502,2011.
87. Jacobs EJ, Newton CC, Wang Y, Patel AV, McCullough ML, Campbell PT, Thun MJ, Gapstur SM. Waist circumference and all-cause mortality in a large US cohort. Archives of internal medicine 170:1293-301,2010.
88. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096,2009.
89. Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clinic proceedings 89:335–345,2014.
90. Kahn HS, Bullard KM, Barker LE, Imperatore G. Differences between adiposity indicators for predicting all-cause mortality in a representative sample of United States non-elderly adults. PloS one 7:e50428,2012.
91. Coutinho T, Goel K, Correa de Sa D, Carter RE, Hodge DO, Kragelund C. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity” . Journal of the American College of Cardiology 61:553–560,2013.
92. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563,2000.
93. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689,2010.
94. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 126:1301–1313,2012.
95. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 112:1821–1830,2003.
96. Cristancho A.G., Lazar M.A. Forming functional fat: A growing understanding of adipocyte differentiation. Nature Reviews Molecular Cell Biology 12:722–734,2011.
97. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44:863–870,1995.
98. Unger RH. Lipotoxic diseases. Annual Review of Medicine 53:319–336,2002.
99. Cao, H., Gerhold, K., Mayers, J. R., Wiest, M. M., Watkins, S. M., Hotamisligil, G. S. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134: 933-944,2008.
100. Truswell AS. Review of dietary intervention studies: effect on coronary events and on total mortality. Australian and New Zealand journal of medicine 24:98-106,1994.
101. Di Angelantonio E, Sarwar N, Perry P. Major lipids, apolipoproteins, and risk of vascular disease. Journal of the American Medical Association 302:1993–2000,2009.
102. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology 8:222–232,2011.
103. Voight BF, Peloso GM, Orho-Melander M. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572–580,2012.
104. Li J, Kaneko T, Qin LQ, Wang J, Wang Y, Sato A. Long-term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among barley, rice, and cornstarch. Metabolism 52:1206-1210,2003.
105. Das N, Mandala A, Bhattacharjee S, Mukherjee D, Bandyopadhyay D, Roy SS. Dietary fat proportionately enhances oxidative stress and glucose intolerance followed by impaired expression of the genes associated with mitochondrial biogenesis. Food & Function 8:1577-1586,2017.
106. Reaven GM. Role of insulin resistance in human disease. Diabetes 37:1595–1607,1988.
107. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194,1991.
108. Anderson DMW, Eastwood MA, Brydon WG. The dietary effects of sodium carboxymethylcellulose in Man. Article in Food Hydrocolloids 1:37-44,1986.
109. Leskauskaite D, Jasutiene I, Kersiene M, Malinauskyte E, Matusevicius P. The effect of carboxymethyl cellulose on the stability of emulsions stabilized by whey proteins under digestion in vitro and in vivo. International Scholarly and Scientific Research & Innovation 7:538-543,2013.
110. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. The Journal of Clinical Endocrinology & Metabolism 97:2482-2488,2012.
111. Stefan N, Schick F, Häring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metabolism 26:292-300,2017.
112. Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, Ouyang P, Sibley CT, Tracy R, Woodward M, Vaidya D. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. Journal of the American College of Cardiology 71:1857-1865,2018.